✦ LIBER ✦

PP35. Use of economic models in an evolving drug evaluation strategy: An example in treatment of metastatic breast cancer

✍ Scribed by J Hutton; R Brown

Book ID: 117665312
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 147 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85947-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN37 AN ECONOMIC EVALUATION OF CIRCULAT

PCN37 AN ECONOMIC EVALUATION OF CIRCULATING TUMOR CELLS DETECTION IN METASTATIC BREAST CANCER

✍ M Rahman; D Malone; E Armstrong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Economic evaluation of fulvestrant as an

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer

✍ Cameron, D A; Camidge, D R; Oyee, J; Hirsch, M 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 498 KB

PCN52 ECONOMIC EVALUATION OF FULVESTRANT

PCN52 ECONOMIC EVALUATION OF FULVESTRANT (FASLODEX,) AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE-RECEPTOR POSITIVE ADVANCED AND METASTATIC BREAST CANCER IN ISRAEL

✍ D Greenberg; M Rabinovich; M Hirsch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

Phase 3 study comparing the use of docet

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

✍ Edgardo Rivera; Jaime A. Mejia; Banu K. Arun; Rosnie B. Adinin; Ronald S. Walter 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

## Abstract ## BACKGROUND Previous studies have evaluated 3‐week and weekly docetaxel schedules in patients with metastatic breast cancer (MBC). The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and m